Updates from Syncona and our portfolio companies
Richard Francis discusses why he has taken on the role of CEO at PureSpring Therapeutics, the importance of Syncona’s role (and expertise in the AAV gene therapy field), and the unique opportunity PureSpring has to make a difference to millions of people as it seeks to develop transformational treatments for patients in areas of high unmet need.
Purespring Therapeutics (Purespring), a kidney-focused AAV gene therapy company, announces that it is intended to appoint Richard Francis as Chief Executive Officer following the completion of its Series A financing of £45.0 million, from 1 February 2021.
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a new Syncona company, Purespring Therapeutics (Purespring), with a £45.0 million Series A financing. Syncona’s holding value in Purespring is £3.9 million following the investment of the first tranche of the Series A commitment and, at the point all current commitments are invested, Syncona will have an 84 per cent stake in the business.